Solodyn Anti-Competition Settlement

Settlement Structure: Claims Made

Active: Closed

Closed Settlement Statement:
According to court documents, the claim submission deadline has passed. Please contact the claims administrator if you have any questions.

Case Summary:

The final two defendants in a class action have agreed to settle a class action alleging that a group of companies engaged in anti-competitive behavior. The complaint alleges that Medicis Pharmaceutical Corp.(“Medicis”), Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. unlawfully settled patent lawsuits covering the drug Solodyn. The result of this was a delay in the availability of generic equivalents, causing consumers to pay more for treatment. Previously, Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. settled; now Medicis and Impax are settling.

Docket Number:

1:14-md-2503-DJC

Company: Impax Laboratories

Filing Deadline: July 31, 2018

Class Period: July 23, 2009 to February 25, 2018

Objection Deadline: June 18, 2018

Final Approval Hearing: July 18, 2018

Proof of Purchase:

Individuals must sign the claim form under penalty of perjury; third-party payors must provide documentation.

Eligibility:

You may be eligible if you are a consumer who

  • At any time between July 23, 2009 and February 25, 2018,
  • You paid for some or all of the price for for 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg Solodyn and/or its generic versions of one or more of these dosages,
  • In tablet form,
  • For yourself or your family,
  • In Alabama, Alaska, Arizona, Arkansas, California, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, Washington, West Virginia, Wisconsin, Wyoming, the District of Columbia and Puerto Rico.

You are not a class member if you are a flat co-payer (who pays the same amount for branded as generic drugs).

You may be eligible if you are a third-party payor as well. See the criteria in the Notices at https://solodyn.blob.core.windows.net/documents/Solodyn%20LF%20Notice.pdf and https://solodyn.blob.core.windows.net/documents/Solodyn%20LF%20Notice%20FINAL.pdf.

For Medicis, the deadline for objections is May 28, 2018 and the hearing date is July 11, 2018; for Impax, the deadline for objections is June 18, 2018 and the hearing date is July 18, 2018.

Typical Settlement Amount:

The final amount of awards will be determined from the total number of valid claims and amounts paid.

Total Settlement Amount: $43 million

Class Representative Proposed Incentive Fee:

$10,000

Law Firms:
Hilliard & Shadowen LLP
Motley Rice LLC

Claim Form: Solodyn Settlement Claim Form

Case Name: In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation

Settlement Website: Solodyn Settlement Website

Claims Administrator:
AB Data Ltd.

Claims Administrator Contact Information:

In re: Solodyn Antitrust Litigation (End-Payor Action)
c/o A.B. Data Ltd.
P.O. Box 173034
Milwaukee, WI 53217
800-332-7414
info@SolodynCase.com

Tags: Antitrust, Drugs and Generics